Clinical Trial Update: Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether atorvastatin reduces hepatocellular carcinoma risk compared with placebo in patients with liver fibrosis or cirrhosis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cirrhosis
• Liver Fibrosis

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Raymond Chung | Conditions: Liver Fibroses, Cirrhosis | Phase 2 | Status: RECRUITING